Avanir's combinatorial approach to calming dementia-related outbursts among Alzheimer's patients caught the attention of Wall Street on Monday morning. The biotech touted midstage data demonstrating that a match of two treatments--a generic cough suppressant and a long-approved treatment for irregular heartbeats--significantly reduced the level of agitation among the patients in the study.
Eli Lilly's Alzheimer's imaging agent, Amyvid, can't get very far sales-wise without coverage from the Center for Medicare and Medicaid Services (CMS). And as per a September decision, that's something it doesn't have. Now, however, it's fighting back, funding litigation it couldn't file itself.
Researchers have used a new drug compound to successfully reverse brain deficits caused by Alzheimer's in animal models. The compound, TC-2153, inhibits the negative effects of a protein called striatal-enriched tyrosine phosphatase--a process that scientists found is key to restoring functions in learning and memory.
This week a German team presented data from a database analysis study that found a link between a diabetes drug and a slight dip in the risk of developing Alzheimer's.
Jeffrey Cummings is directing one of the few early-stage studies underway on an Alzheimer's therapy. And now that he's scanned the records of clinicaltrials.gov, he's acutely aware of just how small his chosen field is.
Promising to use its technology to enhance the efficacy and safety of currently approved Alzheimer's drugs, Chase Pharmaceuticals says it has now added $21 million in new venture cash.
Merck may lead the industry in developing a new BACE inhibitor for Alzheimer's, but AstraZeneca feels that it has a shot at blockbuster glory in the field as well. And now the pharma giant wants to rope a partner in to share the potential rewards, as well as the high level of risk involved--if not just take over the whole thing.
Researchers at Rice University in Texas have developed a new kind of drug delivery particle: a "tunable" virus that releases a treatment only in the presence of not one but two different enzymes that show elevated levels at the site of a tumor.
About 7 months after splitting her company into two biotechs, CEO Nancy Stagliano has sold iPierian and its preclinical foray against neurodegenerative diseases--including Alzheimer's--to Bristol-Myers Squibb for $175 million down and up to $550 million in milestones.
Researchers at the University of California, San Francisco, have launched a new online database to help reduce the time and cost of conducting clinical trials for brain ailments.